BioAdaptives, Inc. has reported its financial results for the third quarter of 2025, revealing a net loss of $379,502, a significant increase from the $37,649 loss recorded in the same period last year. The company's revenues for the quarter reached $4,632, marking a notable shift from zero revenues in the prior year. For the nine months ending September 30, 2025, total revenues were $7,851, down from $12,669 in the same period of 2024. The increase in operating expenses, which totaled $269,540 for the quarter compared to $121,941 in the previous year, contributed to the larger net loss.
The company's balance sheet as of September 30, 2025, shows total current assets of $108,860, a decrease from $261,885 at the end of 2024. Cash reserves have also declined to $59,273 from $137,470. Current liabilities decreased to $1,589,570 from $1,725,803, resulting in a working capital deficiency of $1,480,710. The accumulated deficit has grown to $9,897,858, raising concerns about the company's ability to continue as a going concern without additional financing.
Strategically, BioAdaptives has made significant moves, including the launch of its MyndMed™ product, which aims to enhance cognitive function. The company has also initiated limited sales of its PawPa™ Regen dog treats, which are still undergoing market testing. Additionally, BioAdaptives has expanded its product line to include various dietary supplements and medical devices, with plans to enhance its marketing efforts through direct-to-consumer campaigns and partnerships within the telehealth industry.
Operationally, the company has reported a modest increase in customer engagement, although specific user statistics were not disclosed. The total employee headcount remains low, with one full-time executive and reliance on consultants for operational needs. The company is actively seeking to raise capital through equity markets to support its operations and product development, as it anticipates continued losses until its new products reach their sales potential. The outlook remains cautious, with management acknowledging the need for additional financing to sustain operations and achieve profitability.
About BIOADAPTIVES, INC.
BioAdaptives, Inc. develops, markets, and distributes natural plant, fungi, and algal-based nutraceutical products and medical devices aimed at improving health and wellness for humans and animals. Its product portfolio focuses on weight management, anti-aging, antiviral functions, and cognitive enhancement. The company employs proprietary formulations and clinical research, targeting health-conscious consumers through direct-to-consumer digital marketing, telehealth partnerships, and affiliate programs, while outsourcing manufacturing to maintain operational flexibility.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.